E

arly last year, a former Valeant Pharmaceuticals (VRX) executive told Congress that, when the company took huge price hikes on two life-saving heart drugs in 2013, the drug maker believed the move “should not reduce patient access.”

He was wrong.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.

X